Anti-ROR1 CAR-T cells: Architecture and performance

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is crucial in development and overexpressed in various malignancies.
• ROR1 presents a promising therapeutic target for cancer treatment due to its differential expression.
• Chimeric antigen receptor (CAR)-T cell therapy, specifically ROR1 CAR-T cells, offers a personalized approach for recurrent cancers.

Purpose of the Study:

• To review the biological functions and therapeutic relevance of ROR1.
• To discuss the development, evaluation, and safety of ROR1 CAR-T cells in research and clinical trials.
• To explore combination strategies to overcome challenges in ROR1 CAR-T cell therapy.

Main Methods:

• Review of existing literature on ROR1 biology and function.
• Analysis of ROR1 CAR-T cell designs, preclinical data, and clinical trial outcomes (e.g., NCT02706392).
• Discussion of ROR1's role in tumor microenvironment and heterogeneity.

Main Results:

• ROR1's significant role in embryonic development and aberrant expression in cancers like leukemia, lymphoma, and solid tumors.
• ROR1 CAR-T cells demonstrate potential as a personalized therapy for refractory malignancies.
• Tumor cell heterogeneity and the tumor microenvironment pose significant challenges to CAR-T cell efficacy.

Conclusions:

• ROR1 is a validated and attractive target for cancer immunotherapy.
• ROR1 CAR-T cell therapy is a viable strategy, but requires optimization to overcome resistance mechanisms.
• Combination therapies targeting ROR1 alongside other antigens or resistance pathways may enhance clinical outcomes.